Temporal Trends in Treatment and Outcomes for Advanced Heart Failure With Reduced Ejection Fraction From 1993–2010

DOI Web Site 1 Citations
  • John C. Loh
    From the David Geffen School of Medicine (J.C.L.), Division of Cardiology (J.C., D.A.R., N.L., T.K.H., E.V., G.C.F., T.B.H.), and Department of Medicine (C.-H.T.), University of California, Los Angeles, CA; and Cedars-Sinai Heart Institute, Los Angeles, CA (J.M., M.A.H.).
  • Julie Creaser
    From the David Geffen School of Medicine (J.C.L.), Division of Cardiology (J.C., D.A.R., N.L., T.K.H., E.V., G.C.F., T.B.H.), and Department of Medicine (C.-H.T.), University of California, Los Angeles, CA; and Cedars-Sinai Heart Institute, Los Angeles, CA (J.M., M.A.H.).
  • Darlene A. Rourke
    From the David Geffen School of Medicine (J.C.L.), Division of Cardiology (J.C., D.A.R., N.L., T.K.H., E.V., G.C.F., T.B.H.), and Department of Medicine (C.-H.T.), University of California, Los Angeles, CA; and Cedars-Sinai Heart Institute, Los Angeles, CA (J.M., M.A.H.).
  • Nancy Livingston
    From the David Geffen School of Medicine (J.C.L.), Division of Cardiology (J.C., D.A.R., N.L., T.K.H., E.V., G.C.F., T.B.H.), and Department of Medicine (C.-H.T.), University of California, Los Angeles, CA; and Cedars-Sinai Heart Institute, Los Angeles, CA (J.M., M.A.H.).
  • Tamara K. Harrison
    From the David Geffen School of Medicine (J.C.L.), Division of Cardiology (J.C., D.A.R., N.L., T.K.H., E.V., G.C.F., T.B.H.), and Department of Medicine (C.-H.T.), University of California, Los Angeles, CA; and Cedars-Sinai Heart Institute, Los Angeles, CA (J.M., M.A.H.).
  • Elizabeth Vandenbogaart
    From the David Geffen School of Medicine (J.C.L.), Division of Cardiology (J.C., D.A.R., N.L., T.K.H., E.V., G.C.F., T.B.H.), and Department of Medicine (C.-H.T.), University of California, Los Angeles, CA; and Cedars-Sinai Heart Institute, Los Angeles, CA (J.M., M.A.H.).
  • Jaime Moriguchi
    From the David Geffen School of Medicine (J.C.L.), Division of Cardiology (J.C., D.A.R., N.L., T.K.H., E.V., G.C.F., T.B.H.), and Department of Medicine (C.-H.T.), University of California, Los Angeles, CA; and Cedars-Sinai Heart Institute, Los Angeles, CA (J.M., M.A.H.).
  • Michele A. Hamilton
    From the David Geffen School of Medicine (J.C.L.), Division of Cardiology (J.C., D.A.R., N.L., T.K.H., E.V., G.C.F., T.B.H.), and Department of Medicine (C.-H.T.), University of California, Los Angeles, CA; and Cedars-Sinai Heart Institute, Los Angeles, CA (J.M., M.A.H.).
  • Chi-Hong Tseng
    From the David Geffen School of Medicine (J.C.L.), Division of Cardiology (J.C., D.A.R., N.L., T.K.H., E.V., G.C.F., T.B.H.), and Department of Medicine (C.-H.T.), University of California, Los Angeles, CA; and Cedars-Sinai Heart Institute, Los Angeles, CA (J.M., M.A.H.).
  • Gregg C. Fonarow
    From the David Geffen School of Medicine (J.C.L.), Division of Cardiology (J.C., D.A.R., N.L., T.K.H., E.V., G.C.F., T.B.H.), and Department of Medicine (C.-H.T.), University of California, Los Angeles, CA; and Cedars-Sinai Heart Institute, Los Angeles, CA (J.M., M.A.H.).
  • Tamara B. Horwich
    From the David Geffen School of Medicine (J.C.L.), Division of Cardiology (J.C., D.A.R., N.L., T.K.H., E.V., G.C.F., T.B.H.), and Department of Medicine (C.-H.T.), University of California, Los Angeles, CA; and Cedars-Sinai Heart Institute, Los Angeles, CA (J.M., M.A.H.).

Bibliographic Information

Other Title
  • Findings From a University Referral Center

Description

<jats:sec> <jats:title>Background—</jats:title> <jats:p>Randomized trials have demonstrated the efficacy of several new therapies for heart failure (HF) with reduced ejection fraction over the preceding 2 decades. This study investigates whether these therapeutic advances have translated into improvement in outcomes for patients with advanced HF referred to a heart transplant center.</jats:p> </jats:sec> <jats:sec> <jats:title>Methods and Results—</jats:title> <jats:p>Patients with HF (n=2507) referred to a single university center were analyzed in three 6-year eras during which medical and device therapies were evolving: 1993 to 1998 (era 1), 1999 to 2004 (era 2), and 2005 to 2010 (era 3). Impaired hemodynamics and comorbidities were more frequent at time of referral in later eras, whereas other HF severity parameters where similar or improved. Successive eras had greater usage of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, β-blockers, aldosterone antagonists, implantable cardioverter defibrillators, and cardiac resynchronization therapy, consistent with evolving evidence and guideline recommendations over the study period. All-cause mortality and sudden death were significantly lower in era 2 and 3 compared with era 1. After multivariable risk adjustment, era 3 had significantly decreased 2- and 3-year all-cause mortality risk and significantly decreased 1- and 3-year sudden death risk compared with era 1. However, progressive HF death and the combined outcome of mortality/urgent transplant/ventricular assist device were modestly increased in the latter eras.</jats:p> </jats:sec> <jats:sec> <jats:title>Conclusions—</jats:title> <jats:p>Over the past 2 decades, patients with advanced HF referred to and managed at a tertiary university referral center have benefited from advances in HF medications and devices, as evidenced by improvements in overall survival and sudden death risk.</jats:p> </jats:sec>

Journal

Citations (1)*help

See more

Details 詳細情報について

Report a problem

Back to top